Skip to content

Permeon, founded in 2011, was a biopharmaceutical company pioneering a breakthrough class of intracellular biologics to target a broad spectrum of previously undruggable targets. Leveraging a technology platform exclusively licensed from Harvard University, the company’s approach centered on remodeling the surfaces of proteins to permit cell penetration without losing structure or activity. Permeon ceased operations in 2015.